Celldex Therapeutics (NASDAQ:CLDX) Upgraded to Strong-Buy at Mizuho

Celldex Therapeutics (NASDAQ:CLDX) was upgraded by investment analysts at Mizuho to a “strong-buy” rating in a research report issued to clients and investors on Monday,Zacks.com reports.

A number of other brokerages have also recently commented on CLDX. Citigroup reduced their price target on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Wells Fargo & Company reduced their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reduced their price target on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Finally, Barclays began coverage on shares of Celldex Therapeutics in a research report on Monday, October 13th. They set an “underweight” rating and a $25.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $44.20.

Celldex Therapeutics Stock Down 4.3%

Shares of CLDX opened at $26.72 on Monday. The business’s 50-day moving average price is $24.83 and its 200-day moving average price is $21.97. Celldex Therapeutics has a twelve month low of $14.40 and a twelve month high of $29.38. The stock has a market cap of $1.77 billion, a PE ratio of -8.88 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.01. Celldex Therapeutics had a negative return on equity of 27.61% and a negative net margin of 3,446.88%.The firm had revenue of $0.73 million for the quarter, compared to analysts’ expectations of $1.13 million. Analysts expect that Celldex Therapeutics will post -2.48 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Celldex Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its holdings in Celldex Therapeutics by 171.7% in the second quarter. Nisa Investment Advisors LLC now owns 1,394 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 881 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 501 shares in the last quarter. GAMMA Investing LLC increased its holdings in shares of Celldex Therapeutics by 6,665.9% during the first quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after acquiring an additional 2,933 shares in the last quarter. Headlands Technologies LLC bought a new position in shares of Celldex Therapeutics during the second quarter valued at $125,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Celldex Therapeutics by 289.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock valued at $147,000 after acquiring an additional 5,387 shares in the last quarter.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.